Hypertension, PulmonaryPhase 3SALTONCT04175600
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
A Phase 3 study testing Selexipag, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor and SOC: Soluble guanylate cyclase stimulator in people with Hypertension, Pulmonary, run by Actelion at 116 sites in 32 countries.
Trial summary
The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo. Read more about this study
- Who is it for?
- Ages 2 to 17 years
- Conditions the study is for
- Hypertension, Pulmonary
- What is being tested?
- Selexipag, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor and SOC: Soluble guanylate cyclase stimulator
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 138 participants
- Where
- 116 sitesin 32 countries
- Study dates
- 16 Jan 2020to 1 Oct 2027
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Participants between greater than or equal to (>=) 2 and less than (<) 18 years of age weighing >=9 kilogram (kg) at randomization
- Pulmonary arterial hypertension (PAH) diagnosis confirmed by documented historical right heart catheterization (RHC) performed at any time before participant's screening
- PAH (World Health Organization [WHO] Group 1), including participants with Down syndrome, of the following etiologies: Idiopathic PAH (IPAH); Heritable PAH (HPAH); PAH associated with congenital heart disease (PAH-associated with congenital heart disease [aCHD]) (PAH with coincidental CHD [that is, a small atrial septal defect, ventricular septal defect, or patent ductus arteriosus that does not itself account for the development of elevated PVR] and if approved by the BCAC) and Post-operative PAH (persisting / recurring/ developing >=6 months after repair of CHD); Drug or toxin-induced; PAH associated with Human immunodeficiency virus (HIV)
- WHO functional class (FC) II and III
- Participants treated with at least 1 PAH-specific treatment, example, an Endothelin receptor antagonist (ERA) and/or a Phosphodiesterase type-5 (PDE-5) inhibitor/soluble guanylate cyclase stimulator, provided that the treatment dose(s) has been stable for at least 3 months prior to first dose of study intervention
Who cannot join
- PAH due to portal hypertension, schistosomiasis, pulmonary veno-occlusive disease, and/or pulmonary capillary hemangiomatosis
- PAH associated with Eisenmenger syndrome
- Previous exposure to Uptravi (selexipag)
- Known concomitant life-threatening disease with a life expectancy <12 months
- Pregnant, planning to become pregnant, or lactating
- Known allergies, hypersensitivity, or intolerance to selexipag or its excipients
Trial locations and contacts
116 sites in 32 countries.
116 sites in 32 countries
United States13 sites
Childrens Hospital Colorado
Aurora, Colorado, 80045
University of Virginia Division of Pediatric Cardiology
Charlottesville, Virginia, 22908
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229
Detroit Medical Center
Detroit, Michigan, 48201
Congenital Heart Center of the University of Florida
Gainesville, Florida, 32610
Texas Children's Hospital
Houston, Texas, 77030
Riley Hospital for Children
Indianapolis, Indiana, 46202
UCLA Medical Center
Los Angeles, California, 90095
Childrens Hospital Of Philadelphia
Philadelphia, Pennsylvania, 19104
Phoenix Children's Hospital
Phoenix, Arizona, 85016
Primary Children's Hospital
Salt Lake City, Utah, 84113
UCSF
San Francisco, California, 94158
Children's National Medical Center
Washington D.C., District of Columbia, 20010
Brazil8 sites
Complexo de Prevencao,Diagnostico,Terapia e Reabilitacao Respiratoria LTDA Hospital Dia do Pulmao
Blumenau, 89030-101
Fundacao Universitaria de Cardiologia - Instituto de Cardiologia e Transplantes do DF
Brasília, 70310-500
Hospital Pequeno Principe
Curitiba, 80250-060
Secretaria da Saude do Estado do Ceara - Hospital Doutor Carlos Alberto Studart Gomes
Fortaleza, 60840-285
Irmandade Santa Casa de Misericordia de Porto Alegre
Porto Alegre, 90020-090
Fundacao Universitaria de Cardiologia
Porto Alegre, 90620-001
Irmandade Santa Casa de Misericordia de Sao Paulo
São Paulo, 01221-020
SPDM - Associacao Paulista para o Desenvolvimento da Medicina - Hospital Sao Paulo
São Paulo, 04024 002
China7 sites
Beijing Anzhen Hospital
Beijing, 100029
Guangzhou Women And Childrens Medical Center
Guangzhou, 510623
Qingdao Women and Children's Hospital 1
Qingdao, 266000
Qingdao Women and Children's Hospital
Qingdao, 266000
Shanghai Childrens Medical Center
Shanghai, 200127
Children S Hospital of Fudan University
Shanghai, 201102
The General Hospital of Northern Theater Command
Shenyang, 110000
Colombia6 sites
Clinica San Rafael
Bogotá, 0000000
Fundacion Neumologica Colombiana
Bogotá, 0000000
Fundacion Santa Fe de Bogota
Bogotá
Clínica Imbanaco S.A.S.
Cali, 760042
Fundacion Cardiovascular de Colombia
Piedecuesta, 681017
Hospital Universidad del Norte
Soledad, 0000000
France6 sites
Hôpital Cardiologique - Chru Lille
Lille, 59037
Hopital de la Timone
Marseille, 13385
CHU Arnaud de Villeneuve
Montpellier, 34295
Hôpital Necker - Enfants Malades
Paris, 75015
Hôpital Cardiologique Du Haut-Lévêque
Pessac, 33604
Chu Hopital Des Enfants
Toulouse, 31059
Italy6 sites
Azienda Ospedaliera Policlinico S. Orsola-Malpighi
Bologna, 40138
ASST Grande Ospedale Metropolitano Niguarda
Milan, 20162
Universta Degli Studi Di Padova
Padova
Ospedale Pediatrico Bambin Gesù
Roma, 00193
IRCCS Policlinico San Donato
S. Donato Milanese, 20097
AOU Città della Salute e della Scienza di Torino, Presidio Ospedale Infantile Regina Margherita
Torino, 10126
Poland6 sites
Uniwersyteckie Centrum Kliniczne
Gdansk, 80 952
Uniwersytecki Szpital Dzieciecy w Krakowie
Krakow, 30-663
Szpital Kliniczny im Karola Jonschera
Poznan, 60 572
Instytut Pomnik Centrum Zdrowia Dziecka
Warsaw, 04-730
Wojewodzki Szpital Specjalistyczny we Wroclawiu
Wroclaw, 51 124
Slaskie Centrum Chorob Serca
Zabrze, 41-800
Russia6 sites
Kazan State Medical University
Kazan', 420012
Kazan State Medical University 1
Kazan', 420059
Scientific and Research Institution of Cardiovascular Diseases Complex Problems
Kemerovo, 650002
Childrens City Clinical Hospital n.a. Bashlyaeva
Moscow, 125373
Veltischev Research and Clinical Institute for Pediatrics of the Pirogov RNRMU
Moscow, 125412
Samara Regional Clinical Cardiological Dispensary
Samara, 443070
Spain6 sites
Hosp Univ A Coruna
A Coruña, 15006
Hosp Univ Vall D Hebron
Barcelona, 08035
Hosp. Sant Joan de Deu
Esplugues de Llobregat, 08950
Hosp. Gral. Univ. Gregorio Maranon
Madrid, 28009
Hosp. Univ. La Paz
Madrid, 28046
Hosp. Virgen Del Rocio
Seville, 41013
Turkey (Türkiye)6 sites
Cukurova Balcali Hospital Application and Research Center
Adana, 01790
Hacettepe University Medical Faculty
Ankara, 06230
CAPA Istanbul University Medical Faculty
Istanbul, 34093
Mehmet Akif Ersoy Training and Research Hospital
Istanbul, 34303
Izmir Tepecik Training and Research Hospital
Izmir, 35020
Behcet Uz Pediatric Diseases and Surgery Training and Research Hospital
Izmir, 35210
Germany4 sites
Universitätsklinikum Freiburg Zentrum
Freiburg im Breisgau, 70106
Universitaetsklinikum Heidelberg
Heidelberg, D-69120
Herzzentrum Leipzig GmbH
Leipzig, 04289
Klinikum der Universitaet Muenchen
München, 81377
South Korea4 sites
Seoul National University Hospital
Seoul, 03080
Samsung Medical Center
Seoul, 06351
Severance Hospital Yonsei University Health System
Seoul, 120-752
Pusan National University Yangsan Hospital
Yangsan, 50612
Ukraine4 sites
Dnipropetrovsk clinical medical center of Mother and Child after prof. Rudnev
Dnipro, 49006
MI 'Dnipropetrovsk Regional Clinical Center of Cardiology and Cardiac Surgery'
Dnipro, 49070
Scientific Practical Medical Center for Pediatric Cardiology and Cardio Surgery of the MOH
Kyiv, 04050
MI Zaporizhzhia Regional Clinical Childrens Hospital of Zaporizhzhia Regional Council
Zaporizhzhya, 69063
Vietnam4 sites
Hanoi Medical University Hospital
Hanoi
Tam Anh Hospital
Ho Chi Minh City, 700000
University Medical Center Ho Chi Minh city
Ho Chi Minh City, 700000
Children's Hospital 1
Ho Chi Minh City
Belgium3 sites
ULB Hôpital Erasme
Brussels, 1070
Universitair Ziekenhuis Gent
Ghent, 9000
Universitaire Ziekenhuizen Leuven
Leuven, 3000
Mexico3 sites
CICUM San Miguel
Guadalajara, 44160
Operadora de Hospitales Angeles SA de CV Hospital Angeles Lomas
México, 52787
Unidad de Investigacion Clinica en Medicina S.C. (UDICEM)
Monterrey, 64718
Taiwan3 sites
Kaohsiung Veterans General Hospital
Kaohsiung City, 813414
National Cheng Kung University Hospital
Tainan, 704
National Taiwan University Hospital
Taipei, 100
Belarus2 sites
State Institution Republican Scientific And Practical Center For Pediatric Surgery
Minsk, 220013
Health Institution 4Th City Children'S Clinical Hospital
Minsk, 220118
Canada2 sites
Stollery Children's Hospital
Edmonton, Alberta, T6G 2B7
Hospital For Sick Children
Toronto, Ontario, M5G 1X8
Israel2 sites
Rambam Medical Center
Haifa, 3109601
Sheba Medical Center
Ramat Gan, 52621
Portugal2 sites
Uls Sao Jose - Hosp. Santa Marta
Lisbon, 1169-024
Uls Sao Joao - Hosp. Sao Joao
Porto, 4200 319
Sweden2 sites
Drottning Silvias barn- och ungdomssjukhus
Gothenburg, 416 50
Skanes universitetssjukhus
Lund, 222 42
Thailand2 sites
Chiang Mai University Hospital
Chiang Mai, 50200
Songklanagarind hospital
Songkhla, 90110
Bulgaria1 site
Multiprofile Hospital For Active Treatment National Cardiology Hospital, Ead
Sofia, 1309
Finland1 site
New Children's Hospital of the Helsinki University Hospital (HUS)
Helsinki, 29
Lithuania1 site
Vilnius University Hospital Santariskiu Clinics
Vilnius, LT08661
Switzerland1 site
Centre Hospitalier Universitaire Vaudois CHUV
Lausanne, 1011
About this study
Official title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged >=2 to <18 Years With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.
Read the detailed description
Pediatric PAH is a rare and progressive disorder associated with considerable morbidity and mortality. Given the significant medical need to develop treatments in children with PAH, further clinical studies in the pediatric population are therefore needed to provide more data for the management of PAH in children. Selexipag (JNJ-67896049) is an orally available, selective, and long-acting non-prostanoid agonist of the prostacyclin receptor approved and commercially available for the treatment of adult participants with PAH. Selexipag and its metabolite possess anti-fibrotic, anti-proliferative, and anti-thrombotic properties. Currently, no medicines targeting prostacyclin pathway are approved for pediatric use in PAH. An effective and orally available therapy acting on the prostacyclin receptor such as selexipag introduced at medically appropriate stage of PAH disease, and primarily in combination with current first-line oral PAH-specific medicines in participants in need of additional therapy because of insufficient disease control would represents a major advance to the therapeutic management of PAH pediatric participants. This study consists of a screening period of up to 6 weeks and a double-blind treatment period, including up-titration and maintenance periods, followed by a 3-year open-label extension period (OLEP) and a 30-day safety follow-up period that occurs after the last dose of study intervention (either double-blind or open-label). Safety, pharmacokinetic and efficacy assessments will be performed during the study. An Independent Data Monitoring Committee (IDMC) will be established to monitor data on an ongoing basis, to review interim data, and to ensure the continuing safety of the participants enrolled in this study. The approximate duration of the study is 8 years.
- Conditions
- Hypertension, Pulmonary
- Being tested
- Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator
- Medical subject headings
- Hypertension, Pulmonary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SelexipagDrug
Also called JNJ-67896049
Selexipag tablet will be administered orally.
PlaceboDrug
Matching placebo tablets will be administered orally.
Standard of Care (SOC): Endothelin receptor antagonistDrug
ERAs will be administered as SOC therapy.
SOC: Phosphodiesterase type 5 (PDE-5) inhibitorDrug
PDE-5 inhibitor will be administered as SOC therapy.
SOC: Soluble guanylate cyclase stimulatorDrug
Soluble guanylate cyclase stimulator will be administered as SOC therapy.
| Study group | Role | What they receive |
|---|---|---|
| Selexipag | Experimental | Participants will receive selexipag based on the body weight on Day 1 and will continue thereafter with twice daily dosing. Selexipag will be uptitrated during the first 12 weeks until the participants reaches the individual maximum tolerated dose (iMTD) or until a maximum dose corresponding to their baseline body-weight category is achieved. Uptitration is followed by a maintenance period after Week 12 until end of treatment (EOT), at the maximum tolerated dose. Participants will continue to receive pulmonary arterial hypertension (PAH)-specific concomitant therapies such as ERAs, PDE-5 inhibitors, and soluble guanylate cyclase stimulator as per local standard-of-care. Receives: Drug: Selexipag; Drug: Standard of Care (SOC): Endothelin receptor antagonist; Drug: SOC: Phosphodiesterase type 5 (PDE-5) inhibitor; Drug: SOC: Soluble guanylate cyclase stimulator |
| Placebo | Placebo comparator | Participants will receive matching placebo based on the body weight on Day 1 and will continue thereafter with twice daily dosing. Participants will continue to receive PAH-specific concomitant therapies such as ERAs, PDE-5 inhibitors, and soluble guanylate cyclase stimulator as per local standard-of-care. Receives: Drug: Placebo; Drug: Standard of Care (SOC): Endothelin receptor antagonist; Drug: SOC: Phosphodiesterase type 5 (PDE-5) inhibitor; Drug: SOC: Soluble guanylate cyclase stimulator |
| Open-Label Extension Period: Selexipag | Experimental | Participants with a positive benefit/risk ratio of selexipag for PAH will be offered selexipag in the open label extension period. Participants on selexipag during the double-blind treatment period will continue treatment at their iMTD during the OLEP, for those previously on placebo, the iMTD will uptitrate selexipag during first 12 weeks until participant reaches iMTD. Participants will continue to receive PAH-specific concomitant therapies such as ERAs, PDE-5 inhibitors, and soluble guanylate cyclase stimulator as per local standard-of-care. Receives: Drug: Selexipag; Drug: Standard of Care (SOC): Endothelin receptor antagonist; Drug: SOC: Phosphodiesterase type 5 (PDE-5) inhibitor; Drug: SOC: Soluble guanylate cyclase stimulator |
What is being measured
The primary outcome is the main question the study is designed to answer.
Double-blind Period: Time to Disease Progression
Time to disease progression: time from randomization to first Clinical Event Committee (CEC)-confirmed disease progression event occurring between date of randomization until double-blind end date (DBED) + 7 days. Disease progression event as adjudicated by CEC, defined as any of the following: death (all causes); atrial septostomy or Potts' anastomosis, or registration on lung transplant list; hospitalization due to worsening pulmonary arterial hypertension (PAH); clinical worsening of PAH. Clinical worsening of PAH was defined as initiation of new PAH-specific therapy or intravenous diuretics or continuous oxygen use and at least 1 of the following: worsening in World Health Organization (WHO) functional class (FC); new occurrence or worsening: of syncope, of at least 2 PAH symptoms (shortness of breath/dyspnea, chest pain, cyanosis, dizziness/near syncope, or fatigue), of signs of right heart failure not responding to oral diuretics. Kaplan-Meier method was used for estimation.
Measured: Placebo arm: Randomization (Day 1) up to 7 days after last dose in the DB treatment (maximum up to 199 weeks); Selexipag arm: Randomization (Day 1) up to 7 days after last dose in the DB treatment (maximum up to 213 weeks)
Secondary outcomes (19)
Double-blind Period: Change in log2 N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 24
Change in log2 NT-proBNP from baseline to Week 24 was reported. Change from baseline to Week 24 in the central laboratory NT-proBNP (nanograms per liter [ng/L]) value, expressed as the log2-transformed ratio of the Week 24 NT-proBNP value over the baseline value: log2 (Week 24 NT-proBNP divided by Baseline NT-proBNP). Clinically, a reduction from baseline in NT-proBNP (ratio < 1) was considered an improvement. The baseline value was the last non-missing assessment obtained before or on the DB start date (DBSD).
Measured: Baseline (Day 1), Week 24
Double-blind Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious AEs (TESAEs)
Number of participants with TEAEs (included serious and non-serious events) and TESAEs during DB period was reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A serious AE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product, or was medically important. TEAEs were defined as any AE occurring on or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 3 days and/or prior to start of OL study administration.
Measured: Placebo arm: Start of treatment (Day 1) up to 3 days after last dose in the DB treatment (maximum up to 198.42 weeks); Selexipag arm: Start of treatment (Day 1) up to 3 days after last dose in the DB treatment (maximum up to 212.42 weeks)
Double-blind Period: Number of Participants With AEs Leading to Premature Discontinuation of Study Treatment
Number of participants with AEs leading to premature discontinuation of study treatment during DB period was reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.
Measured: Placebo arm: Start of treatment (Day 1) up to last dose in the DB treatment (maximum up to 198 weeks); Selexipag arm: Start of treatment (Day 1) up to last dose in the DB treatment (maximum up to 212 weeks)
Double-blind Period: Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Change from baseline in vital signs parameters: systolic and diastolic blood pressure during DB period was reported. Vital signs were measured after the participant has rested at least 5 minutes in sitting position. The baseline value was the last non-missing assessment obtained before or on the DBSD.
Measured: Baseline (Day 1), Weeks 24, 48, 72, and 96
Double-blind Period: Change From Baseline in Vital Signs: Pulse Rate
Change from baseline in vital signs parameter: pulse rate during DB period was reported. Vital signs were measured after the participant has rested for at least 5 minutes in sitting position. The baseline value was the last non-missing assessment obtained before or on the DBSD.
Measured: Baseline (Day 1), Weeks 24, 48, 72, and 96
Double-blind Period: Change From Baseline in Growth Parameter: Body Weight
Change from baseline in growth parameter: body weight during DB period was reported. The baseline value was the last non-missing assessment obtained before or on the DBSD.
Measured: Baseline (Day 1), Weeks 24, 48, 72, and 96
Double-blind Period: Change From Baseline in Growth Parameter: Height
Change from baseline in growth parameter: height during DB period was reported. The baseline value was the last non-missing assessment obtained before or on the DBSD.
Measured: Baseline (Day 1), Weeks 24, 48, 72, and 96
Double-blind Period: Number of Participants With Shift From Baseline in Sexual Maturation (Tanner Stage)
Tanner staging were assessed for pubic hair growth and genitalia development (GD) in males (M) and for pubic hair growth and breast development (BD) in females (F) in stages(S) 1 to 5 and missing data. If a participant had reached Tanner stage 5, no further tanner pubertal stage assessment were to be completed. Tanner stage was assessed in F >=8 years; M >=9 years. Pubic hair growth (M and F) stages: S1: No hair, S2: Downy hair, S3: More coarse and curly hair, S4: Adult-like hair quality; S5: Hair extends to medial surface of thighs. BD in females: S1: Nipple raised a little, rest of breast still flat, S2: Breast bud forms, S3: More elevated, outside areola, S4: Increased breast size, S5: Final adult-size breasts. GD in males: S1: Testes, scrotum, and penis about same size, S2: Enlargement of scrotum, testes, and penis, S3: Enlargement of penis, S4: Penis and glands became larger, S5: Genitalia size and shape same an adult male. Categories with at least 1 non-zero data are reported.
Measured: Placebo arm: Baseline (Day 1) up to 3 days after last dose in the DB treatment (maximum up to 198.42 weeks); Selexipag arm: Baseline (Day 1) up to 3 days after last dose in the DB treatment (maximum up to 212.42 weeks)
Double-blind Period: Number of Participants With Treatment-emergent Electrocardiogram (ECG) Abnormalities
Number of participants with treatment-emergent ECG abnormalities were reported. Any abnormality occurring on or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 3 days was considered to be treatment-emergent. Abnormalities that were not present at baseline were reported. Abnormalities were assessed as per investigator's discretion. The baseline value was the last non-missing assessment obtained before or on the DBSD.
Measured: Placebo arm: Start of treatment (Day 1) up to 3 days after last dose in the DB treatment (maximum up to 198.42 weeks); Selexipag arm: Start of treatment (Day 1) up to 3 days after last dose in the DB treatment (maximum up to 212.42 weeks)
Double-blind Period: Number of Participants With Treatment-emergent (TE) Marked Laboratory Abnormalities
Number of participants with TE marked laboratory abnormalities during DB period was reported. TE marked laboratory abnormalities included hemoglobin, platelet count, leukocyte count, potassium, calcium, thyrotropin, thyroxine free and triiodothyronine free. Any abnormality occurring or worsening at or after the DB study treatment start date through the DB study treatment end date plus 3 days was considered to be treatment-emergent. If the abnormality was present at baseline, then any post-baseline abnormality was considered treatment-emergent only if the post-baseline abnormality was in a category worse than at baseline. HH, HHH, HHHH = marked abnormally high values; LL, LLL = marked abnormally low values. The baseline value was the last non-missing assessment obtained before or on the DBSD.
Measured: Placebo arm: Start of treatment (Day 1) up to 3 days after last dose in the DB treatment (maximum up to 198.42 weeks); Selexipag arm: Start of treatment (Day 1) up to 3 days after last dose in the DB treatment (maximum up to 212.42 weeks)
Double-blind Period: Change From Baseline in Treatment-emergent Laboratory Parameter: Thyroid Stimulating Hormone
Change from baseline in treatment-emergent laboratory parameter: thyroid stimulating hormone during DB period was reported. Any abnormality occurring or worsening at or after the DB study treatment start date through the DB study treatment end date plus 3 days was considered to be treatment-emergent. The baseline value was the last non-missing assessment obtained before or on the DBSD.
Measured: Baseline (Day 1), Weeks 24, 48, 72, and 96
Double-blind Period: Change From Baseline in Treatment-emergent Laboratory Parameter: Hemoglobin
Change from baseline in treatment-emergent laboratory parameter: hemoglobin during DB period was reported. Any abnormality occurring or worsening at or after the DB study treatment start date through the DB study treatment end date plus 3 days was considered to be treatment-emergent. The baseline value was the last non-missing assessment obtained before or on the DBSD.
Measured: Baseline (Day 1), Weeks 24, 48, 72, and 96
Double-blind Period: Change From Baseline in Treatment-emergent Laboratory Parameter: Platelets, Leukocytes
Change from baseline in treatment-emergent laboratory parameter: platelets, leukocytes during DB period was reported. Any abnormality occurring or worsening at or after the DB study treatment start date through the DB study treatment end date plus 3 days was considered to be treatment-emergent. The baseline value was the last non-missing assessment obtained before or on the DBSD.
Measured: Baseline (Day 1), Weeks 24, 48, 72, and 96
Double-blind Period: Change From Baseline in Treatment-emergent Laboratory Parameter: Electrolytes (Sodium, Potassium, Calcium, Bicarbonate and Chloride)
Change from baseline in treatment-emergent laboratory parameter: electrolytes (sodium, potassium, calcium, bicarbonate and chloride) during DB period was reported. Any abnormality occurring or worsening at or after the DB study treatment start date through the DB study treatment end date plus 3 days was considered to be treatment-emergent. The baseline value was the last non-missing assessment obtained before or on the DBSD.
Measured: Baseline (Day 1), Weeks 24, 48, 72, and 96
Double-blind Period: Change From Baseline in Treatment-emergent Laboratory Parameter: Transaminases (Alanine Aminotransferase [ALT] and Aspartate Aminotransferase [AST])
Change from baseline in treatment-emergent laboratory parameter: transaminases (ALT and AST) during DB period was reported. Any abnormality occurring or worsening at or after the DB study treatment start date through the DB study treatment end date plus 3 days was considered to be treatment-emergent. The baseline value was the last non-missing assessment obtained before or on the DBSD.
Measured: Baseline (Day 1), Weeks 24, 48, 72, and 96
Double-blind Period: Change From Baseline in Treatment-emergent Laboratory Parameter: Bilirubin
Change from baseline in treatment-emergent laboratory parameter: bilirubin during DB period was reported. Any abnormality occurring or worsening at or after the DB study treatment start date through the DB study treatment end date plus 3 days was considered to be treatment-emergent. The baseline value was the last non-missing assessment obtained before or on the DBSD.
Measured: Baseline (Day 1), Weeks 24, 48, 72, and 96
Double-blind Period: Time to First Clinical Event Committee (CEC)-Confirmed Hospitalization or Death for Pulmonary Arterial Hypertension (PAH)
Time to first CEC-confirmed hospitalization or death for PAH was calculated as the onset date of the first CEC-confirmed death or hospitalization due to PAH minus date of randomization+1 day. Kaplan-Meier method was used for estimation.
Measured: Placebo arm: Randomization (Day 1) up to 7 days after last dose in the DB treatment (maximum up to 199 weeks); Selexipag arm: Randomization (Day 1) up to 7 days after last dose in the DB treatment (maximum up to 213 weeks)
Double-blind Period: Dose-normalized Steady-state Trough Concentrations (Ctrough,ss,dn) of Selexipag and Its Metabolite ACT-333679 by Age Cohort
Dose-normalized trough plasma concentration at steady-state (Ctrough,ss,dn) was defined as the plasma concentration just prior to the morning dose, with the last study intervention administration one day prior to the PK sampling. Steady-state was considered achieved if the participant has received a stable dose for at least 3 days prior to collection of the plasma sample. PK samples were collected at two protocol-specified visits per participant occurring between Week 16 and end of DB treatment period. Exact visit timing varied by participant.
Measured: Cohort (C) 1: Predose between Week (W) 16 to end of DB treatment period (maximum up to W212); C 2: Predose between Week 16 to end of DB treatment period (maximum up to W198); C 3: Predose between Week 16 to end of DB treatment period (maximum up to W96)
Double-blind Period: Dose-normalized Steady-state Trough Concentrations (Ctrough,ss,dn) of Selexipag and Its Metabolite ACT-333679 by Body Weight (BW)
Dose-normalized steady-state trough concentration (Ctrough,ss,dn) was defined as the plasma concentration just prior to the morning dose, with the last study intervention administration one day prior to the PK sampling. Steady-state was considered achieved if the participant has received a stable dose for at least 3 days prior to collection of the plasma sample. PK samples were collected at two protocol-specified visits per participant occurring between Week 16 and end of DB treatment period. Exact visit timing varied by participant.
Measured: BW >=50kg: Predose between W16 to end of DB treatment period (maximum up to W212); BW >=25-<50kg: Predose between W16 to end of DB treatment period (maximum up to W198); BW >=9- <25kg: Predose between W16 to end of DB treatment period (maximum up to W175)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Nov 2019
- Study start16 Jan 2020
- Primary completion11 Oct 2024
- Study completion1 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Hypertension, PulmonaryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 138 participants (actual)
Sponsor and investigators
- Lead sponsor
- Actelion
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Actelion Clinical Trial, Study director, Actelion
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04175600
- Sponsor's protocol ID
- CR108716
- Other IDs
- AC-065A310, 2019-002817-21, 2022-501012-34-00, 2019
- Acronym
- SALTO
- Status last verified
- Sep 2026
- First submitted
- 8 Nov 2019
- Last updated
- 25 Sep 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu